The management of anti-tuberculosis drug-induced hepatotoxicity.
about
Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control studyNational strategy for the integration of pharmacovigilance in the Moroccan TB Control ProgramPharmacovigilance and moroccan tuberculosis public program: current situationMiliary tuberculosis: Epidemiologicaland clinical analysis of large-case series from moderate to low tuberculosis endemic CountryEffect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus.Hepatic safety of antibiotics used in primary careDrug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients.A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infectionDrug-Induced Liver Injury: Pattern Recognition and Future Directions.Anti-tuberculosis drug-induced hepatitis in renal transplant patient with pulmonary and extra pulmonary tuberculosisA prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.An Update on Drug-induced Liver Injury.Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.
P2860
Q28488142-30597EBD-B2C7-402D-9717-1665A122063EQ33585789-EDA140D2-D5B0-4908-9D0C-88118DE913CAQ33820801-5326350A-985C-4CA9-9F56-25A62B93678FQ34680672-5319123C-9F93-4A77-A35C-E54FA470E718Q35010245-F0736122-E59D-482E-BDEA-7B01D2C8BE2AQ35037383-8B6B4883-BB57-485E-98CE-B48088014F8BQ35534713-759BE42A-6E9C-49E9-8230-230DD4831686Q35786010-05733087-CC02-4D63-9A4C-B8B68496DD0EQ36364005-5D344227-8117-4C4F-8EA7-97BD6E29BF61Q36409687-9D00BC85-08AC-4F75-B939-AB990FEF300FQ36412863-FB2067ED-DF11-4E79-B7CC-2AB1C6241A1AQ37099326-267E0F9F-A4E0-40E8-B648-45A28ED679E4Q37278221-9D3ECE84-8E2A-403C-B0CC-AAC2D6FB5469Q37613267-04EA3A10-CFEF-45F4-A97E-8436DC35DDF1Q37613520-58D754B9-4C32-4C0D-96C7-367D8190FC16Q40723805-4E54EAC7-693E-40DF-80DF-11329E2DB1BB
P2860
The management of anti-tuberculosis drug-induced hepatotoxicity.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
The management of anti-tuberculosis drug-induced hepatotoxicity.
@en
The management of anti-tuberculosis drug-induced hepatotoxicity.
@nl
type
label
The management of anti-tuberculosis drug-induced hepatotoxicity.
@en
The management of anti-tuberculosis drug-induced hepatotoxicity.
@nl
prefLabel
The management of anti-tuberculosis drug-induced hepatotoxicity.
@en
The management of anti-tuberculosis drug-induced hepatotoxicity.
@nl
P2093
P1476
The management of anti-tuberculosis drug-induced hepatotoxicity
@en
P2093
K Tahaoğlu
O Yazicioğlu
P577
2001-01-01T00:00:00Z